308 Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1 to pT3a localized renal cell carcinoma in a comprehensive multi-center study of the CORONA project. Can we improve prognostic discrimination of patients with stage pT3a tumors?

2015 ◽  
Vol 14 (2) ◽  
pp. e308-e308a
Author(s):  
S.D. Brookman-May ◽  
M. May ◽  
I. Wolff ◽  
R. Zigeuner ◽  
G. Hutterer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Size ◽  
Renal Cell ◽  
Prognostic Significance ◽  
Localized Renal Cell Carcinoma ◽  
Multi Center Study ◽  
Perirenal Fat ◽  
Center Study

Prognostic significance of perirenal fat invasion and tumor size in pT1 to pT3a renal cell carcinoma: Results of a comprehensive multicenter study of the CORONA project—Can we improve prognostic discrimination of patients with stage pT3a tumors?

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 416-416 ◽  
Author(s):  
Sabine Doris Brookman-May ◽  
Matthias May ◽  
Richard Zigeuner ◽  
Luca Cindolo ◽  
Shahrokh F. Shariat ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Size ◽  
Renal Cell ◽  
Prognostic Significance ◽  
Multivariable Analysis ◽  
Prognostic Impact ◽  
Fuhrman Grade ◽  
The Impact ◽  
Perirenal Fat

416 Background: The renal cell carcinoma (RCC) TNM system merges perirenal fat invasion (PFI) and renal vein invasion (RVI) as stage pT3a despite limited evidence concerning their prognostic equivalence. Additionally, the prognostic value of PFI compared to pT1-pT2 tumors remains controversial. Methods: Data of 7,595 pT1a-pT3a RCC patients undergoing radical nephrectomy or nephron-sparin surgery were pooled from 12 European and U.S. centers (1999-2010). Patients were grouped according to stages and presence of PFI/RVI, i.e., pT1-2N0M0 (n=6,137; 80.8%), pT3aN0M0+PFI (n=1,036; 13.6%), and pT3aN0M0 (RVI±PFI; n=422; 5.6%). Cancer-specific survival (CSS) was estimated by Kaplan-Meier method. Univariate and multivariable Cox proportional-hazards regression models, sensitivity and discrimination analyses were conducted to evaluate the impact of clinico-pathological parameters on cancer-specific mortality (CSM). Results: Compared to stage pT1-2, patients staged pT3a were significantly more frequently male (58.9 vs. 53.1%), older (65 vs. 62.1 yrs), more often had clear cell RCC (86.1 vs. 77.7%), Fuhrman grade 3-4 (30.5 vs. 13.4%), tumor size >7 cm (39.6% vs. 13%), and less often underwent NSS (7.1 vs. 36.6%; each p<0.001). On multivariable analysis, CSM of both patients with PFI and RVI±PFI was significantly enhanced compared to pT1-2 patients (HR 1.96 and 2.14, resp.; p<0.001), whereas patients featuring PFI only and RVI±PFI did not differ (HR 0.92; p=0.48). Tumor size instead significantly influenced CSM in stage pT3a (HR 1.07; p<0.001) with a 7 cm cut-off yielding the highest c-index. Conclusions: Since the prognostic impact of PFI and RVI on CSM seems to be comparable, merging both as stage pT3a might be justified. Enhanced prognostic discrimination of stage pT3a RCC patients appears to be possible by employing a 7 cm tumor size cut-off within an alternative staging system.

scholarly journals 99P The association between antibiotic use and survival in renal cell carcinoma patients treated with nivolumab: A multi-center study

2020 ◽  
Vol 31 ◽  
pp. S1457
Author(s):  
D.C. Guven ◽  
R. Acar ◽  
E. Yekeduz ◽  
I. Bilgetekin ◽  
N. Kose Baytemur ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Antibiotic Use ◽  
Multi Center Study ◽  
Center Study

Tumor-size breakpoint for prognostic stratification of localized renal cell carcinoma

Urology ◽  
2004 ◽  
Vol 63 (2) ◽  
pp. 235-239 ◽  
Author(s):  
Vincenzo Ficarra ◽  
Tommaso Prayer-Galetti ◽  
Giacomo Novara ◽  
Emiliano Bratti ◽  
Luisa Zanolla ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Size ◽  
Renal Cell ◽  
Prognostic Stratification ◽  
Localized Renal Cell Carcinoma

Prognostic value of loss of chromosome 10q in patients with localized renal cell carcinoma.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 626-626
Author(s):  
Cedric Michel Lebacle ◽  
Aydin Pooli ◽  
Nagesh Rao ◽  
Erika Louise Wood ◽  
Nils Kroeger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Size ◽  
Renal Cell ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Chromosome 10Q ◽  
Risk Of Death ◽  
T Stage ◽  
The Impact

626 Background: Several tumor-suppressor genes have been mapped to chromosome 10q, including PTEN. While loss of 10q is a frequently seen cytogenetic abnormality noted to occur in patients with renal cell carcinoma (RCC), little is known about its prognostic significance. We investigated the association of loss of 10q with pathological features and disease-free survival (DFS) in patients with localized RCC. Methods: All patients from UCLA with primary localized RCC who had tumor cytogenetic analysis were included. Alterations in chromosome 10q was specifically reviewed for this study. Logistic regression analyses were used to assess association of loss of 10q with ISUP grading, and T-stage. Cox proportional hazard modeling and Kaplan-Meier analyses were used to assess the impact of loss of 10q on DFS and OS. Recurrence was defined as any local recurrence or development of new metastasis after surgery. Results: A total of 886 patients were included in this study. Loss of 10q occurred in 68 (7.7%) patients and was more commonly seen in chromophobe subtype (24% vs. 6% in non-chromophobe RCC, p < .0001). Loss of 10q was associated with greater tumor size (mean 6.3 vs 5.1 cm, OR = 1.085 [1.024-1.150], p = .008), T3-stage (37% vs 23%, OR = 1.99 [1.17-3.39], p = .011), and ISUP 3-4 (61% vs 37%, OR = 2.64 [1.58-4.40], p < .0001). On survival analysis, after a mean follow-up of 55 months, these patients had a shorter time to recurrence (Log-rank p = .026) and a worse DFS (HR = 2.15 [1.32-3.50], p = .002) than those without loss of 10q. These findings were confirmed on clear-cell RCC subgroup with also a worse OS (HR = 2.00 [1.09-3.67], p = .026) with an estimated 34% risk of death at 5 years for patients with loss of 10q. Conclusions: Loss of chromosome 10q is a prognostic factor associated with larger tumor size, higher grade and T-stage, and worse survival in patients with localized RCC. Identifying patients with loss of 10q can provide additional prognostic information to clinicopathologic variables.

Sign in / Sign up

Export Citation Format

Share Document